ArticleACS omega2026
One-Pot Tandem Construction of Isoindolinone Derivatives under Visible-Light Photoredox Catalysis.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inspired by the significance of amide bonds and C3-substituted isoindolinones in chemistry and biology, we successfully developed a visible-light photoredox-catalyzed metal-free tandem one-pot construction of C3-alkylated isoindolinones bearing an amide bond from easily accessible benzohydrazides, 2-carboxybenzaldehydes, and 4-alkyl-1,4-dihydropyridines. This facile synthetic method delivers target compounds with yields ranging from 71% to 90% across various structurally modified substrates and is also applicable to gram-level preparation. The established strategy is conducive to enriching compound candidate libraries, which further meet the research demands for discovering novel biologically active substances.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.